Form 4: STERIS plc Senior VP Sells Shares Under Pre-Arranged Trading Plan

John Adam Zangerle, STERIS plc's Senior VP, General Counsel, and Secretary, sold 1,978 ordinary shares on June 13, 2025, pursuant to a Rule 10b5-1 trading plan.

Summary

• John Adam Zangerle, Senior VP, General Counsel, and Secretary of STERIS plc, reported the sale of ordinary shares.
• The transactions occurred on June 13, 2025, and were executed under a Rule 10b5-1(c) pre-arranged trading plan.
• A total of 330 ordinary shares were sold at a weighted average price of $240.63 per share, with prices ranging from $240.20 to $241.17.
• An additional 1,648 ordinary shares were sold at a weighted average price of $241.61 per share, with prices ranging from $241.28 to $241.815.
• Following these transactions, Mr. Zangerle beneficially owns 33,760 ordinary shares.
• Of the beneficially owned shares, 8,713 are restricted and subject to future vesting schedules, with restrictions lapsing between October 1, 2025, and June 5, 2028.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be perceived negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan suggests a planned financial management activity rather than a reactive decision based on new information, mitigating potential negative interpretations.

Positives

• The share sales were conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged and scheduled transaction rather than a reactive sale, which can be viewed as a sign of planned financial management by the insider.

Negatives

• The sale of shares by a senior executive reduces their direct equity alignment with the company, which some investors may interpret as a slight negative, even if pre-planned.

Future Outlook

NA

Industry Context

This document is an insider transaction report (Form 4) and does not provide information related to broader industry trends or competitive analysis. It solely details a specific executive's share dealings.

Stakeholder Impact

• Shareholders may interpret the insider sale differently; however, the disclosure of a 10b5-1 plan typically suggests a pre-planned, non-discretionary transaction, which can reduce concerns about management's confidence in the company's future.

Next Steps

• The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• Future vesting of 8,713 restricted ordinary shares will occur on various dates between October 1, 2025, and June 5, 2028.

Key Dates

Keywords

STERIS plc, STE, Form 4, insider trading, share sale, executive compensation, 10b5-1 plan, John Adam Zangerle, beneficial ownership, restricted shares